| Wissenschaftl. Titel | An open-label, multicenter, single-arm, post-marketing trial to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis presenting with recurrent flare following their initial GPP flare treatment with spesolimab i.v. |
| Erkrankung |
Haut:
Schuppenflechte (Psoriasis)
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 25.01.2024 Admin03
geändert 15.02.2024 Admin02